Asosiy kontentga oʻtish
Maqola

Possibilities of glucagon-like peptide-1 agonists in women of fertile and postmenopausal age against a background of obesity

Л. Б. ЛазебникIrina Rubenovna AgababyanSamarkand State Medical UniversityYu.A. IsmoilovaSamarkand State Medical UniversitySh. Sh. SadikovaSamarkand State Medical University
2026en
ABI

Annotatsiya

The purpose. Optimization of treatment of patients with non-alcoholic fatty liver disease associated with insulin resistance with the GLP-1 receptor agonist liraglutide. Materials and methods: The results of analyses of 139 patients aged 25-60 years with varying degrees of obesity were presented. The study included women from two age groups: those of childbearing age (25-44 years) (n-47) and those of perimenopausal age (45-60 years) (n-55). 37 apparently healthy women served as a control group. The following results were obtained: The inclusion of GLP-1 agonists in the treatment of women from different age groups, with increasing doses starting from 0.6 mg each week and reaching a drug level of 2.4 mg once a week, significantly improved their overall condition. Body weight decreased significantly (p<0.01), the range of physical activity expanded, patients tolerated low-calorie diets more easily, and the psycho-emotional status of women in both groups improved considerably.

Hali tarjima qilinmagan

Identifikatorlar

Iqtiboslar va manbalar